Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host Disease

Clinical trial NCT06824103 · RECRUITING

Trial details

NCT number: NCT06824103
Sponsor: Novartis Pharmaceuticals
Status: RECRUITING
Phase: Phase 4
Study type: INTERVENTIONAL

Graft vs. Host Disease Chronic Graft vs. Host Disease Corticosteroid-refractory Chronic Graft vs. Host Disease

Start date: 2025-09-09
Primary completion: 2029-05-10
Enrollment: 50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.